ArticleJournal of contemporary brachytherapy2026
A novel patient-specific solution for Merkel cell carcinoma in high-dose-rate brachytherapy.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Superficial lesions in anatomically complex areas pose challenges for conventional high-dose-rate (HDR) brachytherapy (BT) techniques. We developed a novel 3D-printed applicator tailored for hand skin cancer, and evaluated its clinical feasibility and advantages. Material and methods: A patient with Merkel cell carcinoma of the right hand, involving the palm, dorsum, and interdigital spaces, was referred for HDR-BT. After initial CT simulation, planning target volume (PTV) was delineated and applicator structure was contoured, to comply with and encompass the PTV. Catheter channels were designed, and the applicator was fabricated as palmar and dorsal components to facilitate setup, using a stereolithography 3D printer with tissue-equivalent, bio-compatible clear resin. The patient underwent a second CT simulation with the applicator and catheters in place, and treatment planning was performed. Pre-treatment dry run confirmed source travel and catheter lengths, and treatment was delivered using a Flexitron HDR-BT afterloader. Results: Twenty-seven catheters achieved PTV coverage of 98.6% at D Conclusions: The patient-specific 3D-printed applicator was successfully applied for skin lesions unsuitable for conventional techniques. Reduced air gaps improved dose conformity, and the semi-rigid, translucent resin enhanced setup reproducibility. The workflow substantially optimized staff resources, offering HDR-BT solution for complex superficial lesions in clinics without in-house printing capabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.